Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 8c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.13 +0.39%
Revenue Growth %: +24.1%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +24.1%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.03), $0.08 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $43.92 million.
Sees Q4 combined net product sales from both HETLIOZ and Fanapt $42 to $48 million
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Anthropic delays planned IPO from October to November - WSJ
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
